Allogeneic Cd56-Positive Cd3-Negative Natural Killer Cells
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
M.D. Anderson Cancer CenterCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 37/ 100
- Competitive Position
- 81/ 100
Competitive context
86 Active assets in the Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide City of Hope Medical Center | Phase 3 | BBB |
Nilotinib Novartis Pharmaceuticals | Phase 4 | BBB |
Fludarabine Fred Hutchinson Cancer Center | Phase 3 | BBB |
Therapeutic Allogeneic Lymphocytes University of Chicago | Phase 2 | BBB |
Romidepsin Center for International Blood and Marrow Transplant Research | Phase 2 | BBB |
View all 50 →
Same molecule, other indications
Allogeneic Cd56-Positive Cd3-Negative Natural Killer Cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →